Typhoid Fever Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Typhoid Fever Market Overview

Typhoid fever is a life-threatening bacterial infection caused by Salmonella enterica serovar Typhi, primarily transmitted through contaminated food and water. The disease is characterised by sustained fever, abdominal pain, headache, and gastrointestinal complications, predominantly affecting populations in regions with inadequate sanitation and limited access to clean water. The typhoid fever market across 8 major markets was valued at USD 496.37 Million in 2025, supported by the rising demand for vaccines and antibiotics, growing awareness of drug-resistant strains, and expanding immunisation programmes. The market is witnessing steady growth fuelled by the accelerating adoption of typhoid conjugate vaccines, increasing investment in diagnostic technologies, and the ongoing global effort to combat antimicrobial resistance.

Typhoid Fever Market Segmentation

Typhoid Fever Market Growth Analysis and Key Influencers

Typhoid Fever Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Typhoid Fever Market Growth Drivers

Rising Prevalence of Drug-Resistant Typhoid Fever to Drive Market Demand

The escalating prevalence of typhoid fever, compounded by the growing emergence of antibiotic-resistant Salmonella Typhi strains, is a fundamental factor driving the growth of the typhoid fever market. According to the Centres for Disease Control and Prevention (CDC), as of December 2024, 89% of the extensively drug-resistant REPJPP01 Salmonella Typhi isolates detected in the United States showed resistance to five major antibiotic classes. This rising antimicrobial resistance is significantly increasing demand for novel treatment options, advanced vaccines, and rapid diagnostic technologies, prompting pharmaceutical companies to invest in expanding their product portfolios and supporting long-term market growth.

Typhoid Fever Market Restraints

Limited Healthcare Infrastructure in Endemic Regions Constrains the Market Expansion

The typhoid fever market and even the typhoid drug and vaccine market is restrained by limited healthcare infrastructure and insufficient access to clean water and sanitation in endemic regions. According to Hancuh et al., 2023, the highest estimated typhoid incidence occurs in the WHO South-East Asian region at 306 cases per 100,000 persons, followed by the Eastern Mediterranean at 187, and the African region at 111 per 100,000 persons. Limited availability of diagnostic tools and trained healthcare professionals in these high-burden areas restricts timely diagnosis and treatment. These barriers collectively reduce treatment access and constrain the overall expansion of the market.

Typhoid Fever Market Opportunities

Expanding Typhoid Conjugate Vaccine Programmes to Accelerate Market Growth

The typhoid fever market is witnessing significant growth opportunities driven by the expanding global rollout of typhoid conjugate vaccines. According to the Coalition Against Typhoid, nearly 150 million children have been vaccinated with TCVs during introduction campaigns as of 2025, with Burkina Faso, Kenya, Bangladesh, and Niger all introducing TCV into routine immunisation in 2025. WHO prequalification of four TCVs and Gavi's commitment of USD 85 million in funding are further accelerating vaccine adoption in endemic countries. These developments are creating substantial growth opportunities and supporting the overall market trajectory.

Typhoid Fever Market Trends

Some of the notable trends in the market include the accelerating adoption of typhoid conjugate vaccines across endemic countries.

Rising Global Adoption of Typhoid Conjugate Vaccines to Elevate Market Landscape

The typhoid fever market is witnessing a significant trend toward the adoption of typhoid conjugate vaccines, which provide longer-lasting immunity, require only a single dose, and are suitable for children older than six months. According to the World Health Organisation, TCVs are recommended for routine use in endemic countries, with four WHO-prequalified TCVs now available. The expanding introduction of TCVs across multiple countries, supported by Gavi funding and increasing government commitment to immunisation programmes, is reshaping the typhoid disease management commercial landscape and driving overall market growth.

Typhoid Fever Market Share

Antibiotics Segment to Lead the Treatment Type Segment of Typhoid Fever Market

Among the various treatment types, the antibiotics segment is expected to maintain its dominant position in the typhoid fever market due to the established reliance on antibiotic therapy as the primary treatment modality for confirmed typhoid cases. According to the World Health Organisation, antibiotics remain the recommended first-line treatment for typhoid fever, with azithromycin and ceftriaxone widely prescribed for both uncomplicated and drug-resistant cases. The rising demand for Salmonella Typhi infection therapeutics and the growing focus on developing novel antibiotics to combat resistant strains further reinforces this segment's market leadership.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Typhoid Fever Market Analysis by Region

The United States is expected to maintain its dominant position in the typhoid fever market across the 8 major markets, driven by well-established healthcare infrastructure, advanced medical facilities, and a high number of drug approvals. According to the CDC, extensively drug-resistant typhoid fever cases continue to be reported in the country, driving investment in advanced diagnostics and treatment options. The presence of leading pharmaceutical companies and robust clinical trial activity in the enteric fever therapy industry further support the United States' market leadership during the forecast period.

Leading Players in the Typhoid Fever Market

Key Questions Answered in the Typhoid Fever Market Report

• What was the typhoid fever market value in 2025?
• What is the typhoid fever market forecast outlook for 2026-2035?
• What major factors aid the demand for the typhoid fever market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major typhoid fever market trends?
• Which treatment type is expected to dominate the market segment?
• Which disease type is expected to dominate the market segment?
• Which route of administration is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Who are the key players in the typhoid fever market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Direct collection, structuring, and analysis of the scientific data from the Centre for Disease Control and the World Health Organization, combined with first-hand monitoring of regulatory circulars and strategic developments from leading market participants, forming the quantitative and competitive foundation of the report.
• Secondary Research: The analysis draws on epidemiological and clinical data from the Centre for Disease Control like the data summary on REPJPP01, an antibiotic resistant strain of Salmonella Typhi and the Morbidity and Mortality Weekly Report (MMWR) on typhoid surveillance, incidence estimates etc; insights from the 14^th International Conference on Typhoid; peer-reviewed literature on a strategic model for developing vaccines against neglected diseases like typhoid; and public disclosures, financial statements, and strategic announcements from leading market participants used in the competitive and strategic-initiative analyses.
• Validation: Quantitative estimates are triangulated using top-down and bottom-up market modelling to ensure internal consistency across segments and the overall market.